Matsuyama H, et al. - In this trial, the authors aimed to identify the optimal dose of high dose cisplatin (CDDP) in concurrent chemoradiotherapy (CCRT) for patients with advanced head and neck squamous cell carcinoma (SCC) in Japan. They noted that in terms of safety, a CDDP dose of 80 mg/m² was the optimal dose. CCRT completion rate, response rate, and rates of adverse events were not inferior for a CDDP dose of 80 mg/mmg/m² vs a dose of 100 mg/mmg/m². Hence, a dose of 80 mg/m² was recommended in CCRT for the Japanese.